Roche Pharmaceutical Development and Sales Overview

MS franchise: Ocrevus #1 treatment in US and now also in EU-5 MS development programs well on track Roche Q3 update • >250.000 patients treated globally • #1 treatment in US and EU-5, both in total share and new to brand share Higher persistence than other MS medicines ⚫Ph Ill program (FENhance I/II, FENtrepid) for fenebrutinib in RMS and PPMS on track ⚫ Ph III (OCARINA II) Ocrevus SC with strong recruitment; results expected in 2023 Outlook 2022 • US/EU: Further market share gains expected CHFM YoY CER growth 1,750 1,500 1,250 +16% . +7% +37% 1,000 +48% 750 500 250 0 Q3 19 Q3 20 Q3 21 Q322 . US ■Europe International CER=Constant Exchange Rates; MS-multiple sclerosis; SC=subcutaneous; RMS=relapsing MS; PPMS-primary progressive MS 25

View entire presentation